This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Montefiori, D. C.
Right arrow Articles by Rosenberg, E. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Montefiori, D. C.
Right arrow Articles by Rosenberg, E. S.

 Previous Article  |  Next Article 

Journal of Virology, November 2001, p. 10200-10207, Vol. 75, No. 21
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.21.10200-10207.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Neutralizing Antibodies Associated with Viremia Control in a Subset of Individuals after Treatment of Acute Human Immunodeficiency Virus Type 1 Infection

David C. Montefiori,1,* Tanya S. Hill,1 Ha T. T. Vo,1 Bruce D. Walker,2 and Eric S. Rosenberg2

Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710,1 and Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 021142

Received 31 May 2001/Accepted 27 July 2001

Immediate treatment of acute human immunodeficiency virus type 1 (HIV-1) infection has been associated with subsequent control of viremia in a subset of patients after therapy cessation, but the immune responses contributing to control have not been fully defined. Here we examined neutralizing antibodies as a correlate of viremia control following treatment interruption in HIV-1-infected individuals in whom highly active antiretriviral therapy (HAART) was initiated during early seroconversion and who remained on therapy for 1 to 3 years. Immediately following treatment interruption, neutralizing antibodies were undetectable with T-cell-line adapted strains and the autologous primary HIV-1 isolate in seven of nine subjects. Env- and Gag-specific antibodies as measured by enzyme-linked immunosorbent assay were also low or undetectable at this time. Despite this apparent poor maturation of the virus-specific B-cell response during HAART, autologous neutralizing antibodies emerged rapidly and correlated with a spontaneous downregulation in rebound viremia following treatment interruption in three subjects. Control of rebound viremia was seen in other subjects in the absence of detectable neutralizing antibodies. The results indicate that virus-specific B-cell priming occurs despite the early institution of HAART, allowing rapid secondary neutralizing-antibody production following treatment interruption in a subset of individuals. Since early HAART limits viral diversification, we hypothesize that potent neutralizing-antibody responses to autologous virus are able to mature and that in some persons these responses contribute to the control of plasma viremia after treatment cessation.

* Corresponding author. Mailing address: Department of Surgery, Box 2926, Duke University Medical Center, Durham, NC 27710. Phone: (919) 684-5278. Fax: (919) 684-4288. E-mail: monte{at}duke.edu.

Journal of Virology, November 2001, p. 10200-10207, Vol. 75, No. 21
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.21.10200-10207.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Davis, K. L., Bibollet-Ruche, F., Li, H., Decker, J. M., Kutsch, O., Morris, L., Salomon, A., Pinter, A., Hoxie, J. A., Hahn, B. H., Kwong, P. D., Shaw, G. M. (2009). Human Immunodeficiency Virus Type 2 (HIV-2)/HIV-1 Envelope Chimeras Detect High Titers of Broadly Reactive HIV-1 V3-Specific Antibodies in Human Plasma. J. Virol. 83: 1240-1259 [Abstract] [Full Text]  
  • Huber, M., von Wyl, V., Ammann, C. G., Kuster, H., Stiegler, G., Katinger, H., Weber, R., Fischer, M., Stoiber, H., Gunthard, H. F., Trkola, A. (2008). Potent Human Immunodeficiency Virus-Neutralizing and Complement Lysis Activities of Antibodies Are Not Obligatorily Linked. J. Virol. 82: 3834-3842 [Abstract] [Full Text]  
  • Verity, E. E., Zotos, D., Wilson, K., Chatfield, C., Lawson, V. A., Dwyer, D. E., Cunningham, A., Learmont, J., Dyer, W., Sullivan, J., Churchill, M., Wesselingh, S. L., Gabuzda, D., Gorry, P. R., McPhee, D. A. (2007). Viral Phenotypes and Antibody Responses in Long-Term Survivors Infected with Attenuated Human Immunodeficiency Virus Type 1 Containing Deletions in the nef and Long Terminal Repeat Regions. J. Virol. 81: 9268-9278 [Abstract] [Full Text]  
  • Quakkelaar, E. D., van Alphen, F. P. J., Boeser-Nunnink, B. D. M., van Nuenen, A. C., Pantophlet, R., Schuitemaker, H. (2007). Susceptibility of Recently Transmitted Subtype B Human Immunodeficiency Virus Type 1 Variants to Broadly Neutralizing Antibodies. J. Virol. 81: 8533-8542 [Abstract] [Full Text]  
  • Shibata, J., Yoshimura, K., Honda, A., Koito, A., Murakami, T., Matsushita, S. (2007). Impact of V2 Mutations on Escape from a Potent Neutralizing Anti-V3 Monoclonal Antibody during In Vitro Selection of a Primary Human Immunodeficiency Virus Type 1 Isolate. J. Virol. 81: 3757-3768 [Abstract] [Full Text]  
  • Dickover, R., Garratty, E., Yusim, K., Miller, C., Korber, B., Bryson, Y. (2006). Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants.. J. Virol. 80: 6525-6533 [Abstract] [Full Text]  
  • Deeks, S. G., Schweighardt, B., Wrin, T., Galovich, J., Hoh, R., Sinclair, E., Hunt, P., McCune, J. M., Martin, J. N., Petropoulos, C. J., Hecht, F. M. (2006). Neutralizing Antibody Responses against Autologous and Heterologous Viruses in Acute versus Chronic Human Immunodeficiency Virus (HIV) Infection: Evidence for a Constraint on the Ability of HIV To Completely Evade Neutralizing Antibody Responses.. J. Virol. 80: 6155-6164 [Abstract] [Full Text]  
  • Skrabal, K., Saragosti, S., Labernardiere, J.-L., Barin, F., Clavel, F., Mammano, F. (2005). Human Immunodeficiency Virus Type 1 Variants Isolated from Single Plasma Samples Display a Wide Spectrum of Neutralization Sensitivity. J. Virol. 79: 11848-11857 [Abstract] [Full Text]  
  • Rusert, P., Kuster, H., Joos, B., Misselwitz, B., Gujer, C., Leemann, C., Fischer, M., Stiegler, G., Katinger, H., Olson, W. C., Weber, R., Aceto, L., Gunthard, H. F., Trkola, A. (2005). Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors. J. Virol. 79: 8454-8469 [Abstract] [Full Text]  
  • Decker, J. M., Bibollet-Ruche, F., Wei, X., Wang, S., Levy, D. N., Wang, W., Delaporte, E., Peeters, M., Derdeyn, C. A., Allen, S., Hunter, E., Saag, M. S., Hoxie, J. A., Hahn, B. H., Kwong, P. D., Robinson, J. E., Shaw, G. M. (2005). Antigenic conservation and immunogenicity of the HIV coreceptor binding site. JEM 201: 1407-1419 [Abstract] [Full Text]  
  • Howe, L., Craigo, J. K., Issel, C. J., Montelaro, R. C. (2005). Specificity of serum neutralizing antibodies induced by transient immune suppression of inapparent carrier ponies infected with a neutralization-resistant equine infectious anemia virus envelope strain. J. Gen. Virol. 86: 139-149 [Abstract] [Full Text]  
  • Trkola, A., Kuster, H., Leemann, C., Oxenius, A., Fagard, C., Furrer, H., Battegay, M., Vernazza, P., Bernasconi, E., Weber, R., Hirschel, B., Bonhoeffer, S., Gunthard, H. F. (2004). Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. Blood 104: 1784-1792 [Abstract] [Full Text]  
  • Zhang, H., Huang, Y., Fayad, R., Spear, G. T., Qiao, L. (2004). Induction of Mucosal and Systemic Neutralizing Antibodies against Human Immunodeficiency Virus Type 1 (HIV-1) by Oral Immunization with Bovine Papillomavirus-HIV-1 gp41 Chimeric Virus-Like Particles. J. Virol. 78: 8342-8348 [Abstract] [Full Text]  
  • Huang, C.-c., Venturi, M., Majeed, S., Moore, M. J., Phogat, S., Zhang, M.-Y., Dimitrov, D. S., Hendrickson, W. A., Robinson, J., Sodroski, J., Wyatt, R., Choe, H., Farzan, M., Kwong, P. D. (2004). Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc. Natl. Acad. Sci. USA 101: 2706-2711 [Abstract] [Full Text]  
  • Burrer, R., Haessig-Einius, S., Aubertin, A.-M., Moog, C. (2003). Polyclonal Immunoglobulin G from Patients Neutralizes Human Immunodeficiency Virus Type 1 Primary Isolates by Binding Free Virions, but without Interfering with an Initial CD4-Independent Attachment of the Virus to Primary Blood Mononuclear Cells. J. Virol. 77: 11385-11397 [Abstract] [Full Text]  
  • Montefiori, D. C., Altfeld, M., Lee, P. K., Bilska, M., Zhou, J., Johnston, M. N., Gao, F., Walker, B. D., Rosenberg, E. S. (2003). Viremia Control Despite Escape from a Rapid and Potent Autologous Neutralizing Antibody Response After Therapy Cessation in an HIV-1-Infected Individual. J. Immunol. 170: 3906-3914 [Abstract] [Full Text]  
  • Villinger, F., Mayne, A. E., Bostik, P., Mori, K., Jensen, P. E., Ahmed, R., Ansari, A. A. (2002). Evidence for Antibody-Mediated Enhancement of Simian Immunodeficiency Virus (SIV) Gag Antigen Processing and Cross Presentation in SIV-Infected Rhesus Macaques. J. Virol. 77: 10-24 [Abstract] [Full Text]  
  • Craigo, J. K., Leroux, C., Howe, L., Steckbeck, J. D., Cook, S. J., Issel, C. J., Montelaro, R. C. (2002). Transient immune suppression of inapparent carriers infected with a principal neutralizing domain-deficient equine infectious anaemia virus induces neutralizing antibodies and lowers steady-state virus replication. J. Gen. Virol. 83: 1353-1359 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»